CPA
CSTL icon

Capital Performance Advisors’s Castle Biosciences CSTL Stock Holding History

Capital Performance Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33
Closed -$941 – 757
2024
Q3 		$941 Buy
+33
New +$840 ﹤0.01% 1938

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Performance Advisors's CSTL Position: Q4 2024 in Review

Capital Performance Advisors sold out of Castle Biosciences (CSTL) in Q4 2024, closing a stake of 33 shares — an estimated $941 sold.

Capital Performance Advisors first reported a position in CSTL in Q3 2024 and held it in 1 quarter. The position peaked at $941 in Q3 2024. 197 funds tracked by Wall St. Rank hold CSTL as of Q4 2024.

  • Capital Performance Advisors reported no remaining Castle Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 33 Castle Biosciences shares in Q4 2024, an estimated $941.
  • Capital Performance Advisors first reported a position in Castle Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Castle Biosciences position peaked at $941 in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.